The U.S. Market for Over-the-Counter Anti-Infectives

Questions: Discounts, Updates etc.

Pages: 200

Price (Single): $3,000.00

Price (Company): $6,000.00

Publication Date: 2006-01-01

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products.

This comprehensive report examines all aspects of the U.S. OTC market, including 5-year sales performance by brand and by marketer for the following categories of products:

Antifungals
- Jock-Itch Products
- Vaginal Yeast Infection Products
- Athlete’s Foot Products
Antiseptic/Antibiotics
Antiparasitics

The report also provides in-depth coverage consumer demographic and preferences and analyses of sales channels. Th competitive picture is extensively examined in terms of market share by player, market share by brand, promotional spend, new product development, and much more. Profiles of the top competitors round out the picture of the marketplace.

The methodology for assembling this report included a combination of primary and secondary research. Information Resources Inc. (IRI) and Simmons Market Research Bureau (SMRB) provided primary research findings; secondary research included such material as published reports, news stories, and company literature and documents.

Chapter One: Executive Summary

Report Scope
Categories
Methodology
Product Description
- Overview
- Antiseptics
- Antibiotics
- Antifungal Treatments
- Anti-Parasitic (Lice) Treatments
The Market
Market Composition
Key Trends & Issues
- Seasonality in Anti-fungal Treatment Sales
- Most Drugs Approved in 2004 Since 1996
- Lack of Rx-to-OTC Switches for Anti-infectives
- Growing Healthcare Costs
The Online Healthcare Market
- The Growth of Generics
Market Forecast
- The Marketers
- Private Labels
The Consumer
- Marketing Dynamics

Chapter Two: The Market

Product Description
- Overview
- Antiseptics
- Antibiotics
- Antibiotic Resistance
- Antifungal Treatments
Introduction to Infections
- Jock Itch (Tinea Cruris)
- Vaginal Yeast Infection (Vulvovaginal Candidiasis)
- Athlete’s Foot (Tinea Pedis)
- Antiparasitic (Lice) Treatments
- Regulatory Environment
- Brand and Generic Names
- The Cost Factor
- Approval Process
OTC and Prescription Drugs
Rx-to-OTC Switch
- Labeling Issues
- Industry Overview
- Market Composition
- Anti-fungal Treatment
- First Aid Products
- Anti-Parasitic Treatments
Key Trends & Issues
- Seasonality in Antifungal Treatment Sales
- Number of New Drug Approvals
- More Botanicals, Fewer Preservatives
- Lack of Rx-to-OTC Switches for Anti-Infectives
- Growing Healthcare Costs
- Children — A Key Demographic
- Growing Insurer Share in Healthcare
- Pharma’s Revenue Expectations
- Importation of Drugs
- Growing Share of Uninsured Population
- Lower Drug Costs Through Outsourcing
- Consumer Acceptance of Self-Medication
- The Online Healthcare Market
- The Insurer Push
- Direct-to-Consumer Advertising
- The Growth of Generics
Market Forecast

Chapter Three: The Marketers

Competitive Analysis

Top Marketers and Products

Antifungal Treatments

Flat Sales for Jock Itch Brands
Lotrimin Ultra Outperforms Category
Monistat Dominates Yeast Infection Treatments
Athlete’s Foot — Schering-Plough at the Top

Antiseptics/Antibiotics

First Aid Brands Thrive

Anti-Parasitics

Lice Treatments Suffer

Private Labels

Mergers & Acquisitions

Pfizer Acquires Pharmacia Corp.
Novartis AG - Eon Labs
Novartis Acquires Vagistat from Bristol-Myers Squibb
Mylan Laboratories Acquires King Pharmaceuticals

Chapter Four: The Consumer

Simmons Survey
Overview
First Aid
- First Aid Bandages
- Sprays, Gels & Wipes Emerging
- Band-Aid, The Consumer’s Favorite
Antifungal Treatments
- Foot and Nail Fungus
- Older Population
- Roper Public Affairs Survey
- Men more Likely to Suffer from Athlete’s Foot
- Central and Pacific States Index Higher for Athlete’s Foot
- Foot Problem Survey
- Athlete’s Foot & Nail Fungus Treatment Users
- Yeast Infection
- Yeast Treatment Usage by Type
- African-American Women Index Higher
- Monistat Leads All
Consumer Attitudes
- Preference for OTC Drugs and Private Labels
- Store Brand Buyers
Chapter Five: Marketing Dynamics
- Overview
- Advertising and Promotion
  - Pfizer Tops Ad Spend List
  - Novartis’ DTC Campaign
  - Monistat Intimate Skincare Launch
- Distribution & Retailing
  - Drug Store Chains
  - e-Pharmacies
- Retail trends
  - Drug Stores Outpace Overall Market
- Store Clinics
  - Rite Aid Tests Hispanic Stores
  - Drug Chains Aid Consumers
  - Pharmacy Recommendations
  - Walgreens’ Health Initiatives
- New Product Introductions
  - Consumers Prefer Quick-Relief & Natural Products
  - First Aid for Kids
  - Limited Yeast Infection Products
  - Hypoallergenic Anti-Infectives
  - Scented/Flavored Products
- Innovation
  - Curad Bandages
  - Brand
  Chapter Six: Company Profiles
- Johnson & Johnson
  - Overview
  - OTC Anti-Infective Product Line
  - Band-Aid
  - Monistat
  - Performance
- Pfizer Inc.
  - Overview
  - OTC Anti-Infective Product Line
  - Focus on Pharmaceuticals and Healthcare
  - Performance
- Bayer Group
  - Overview
  - U.S. Operations
  - OTC Anti-Infective Product Line
  - Performance
  - Bayer, Expanding its Reach
- Bristol-Myers Squibb Company
  - Overview
  - OTC Anti-Infectives
  - Performance
  - Renewed Strategy - Focus on Prescription Drugs
- Novartis AG
  - Overview
  - The Consumer Health Division
  - OTC Anti-Infective Product Line
  - Performance
  - R&D: The Company’s Lifeblood
- Schering Plough Corporation
  - Overview
  - OTC Anti-Infective Product Line
  - Performance
- Combe Inc.
  - Overview
  - OTC Anti-Infective Product line
  - Performance
- Chattem Inc.
  - Overview
  - OTC Anti-Infective Product Line
- Performance
  - Future Strategy
- Merz Pharmaceuticals
  - Overview
  - Performance
- Beiersdorf AG
  - Overview
  - OTC Anti-Infective Product Line
  - Performance
  - Future Strategy
- Taro Pharmaceuticals Industries Ltd.
  - Overview
  - R&D
  - Drug Portfolio
  - Performance
  - FDA Approves Taro’s Mupirocin Ointment
- Stiefel Laboratories Inc.
  - Overview
  - Skin Care Products
  - Sarna #1 Itch Relief Cream for 3 Years
  - Performance
  - FDA Approval for MimyX Cream
- Alva-Amco Pharmacal Companies Inc.
  - Overview
  - Product Portfolio
  - Performance
  - FungiCure 2004 Nail Hygiene Survey
- Becton Dickinson & Company
  - Overview
  - Anti-Infective Products
  - Performance
  - FDA Approval for BD Diagnostic Products
- Playtex Products Inc.
  - Overview
  - Product Portfolio
  - Performance
  - Core Category Acquisitions
  Appendix: Addresses of Select Marketers
  List of Exhibits
  
  Chapter One: Executive Summary
  - Table 1-1: U.S. Retail OTC Anti-Infective Sales 2000-2005
  - Table 1-2: IRI-Tracked Retail Anti-Infective Category Sales 2005
  - Table 1-3: IRI-Tracked Retail Sales of U.S. Top 10 Anti-InfectiveMarketers 2004-2005
  - Table 1-4: IRI-Tracked Retail Sales of U.S. Top 10 Anti-InfectiveBrands 2004-2005

Chapter Two: The Market

Table 2-1: Stages in Clinical Trial
Figure 2-1: U.S. Drug Development and Patent Process
Figure 2-2: U.S. OTC Review Process
Figure 2-3: U.S. Retail OTC Anti-infective Sales, 2000-2005 (E)
Table 2-2: IRI-Tracked U.S. Retail Sales of OTC Anti-Infectives by Category (Antifungals, First Aid, Antiparasitics) 2000-2005 (E)
Table 2-3: IRI-Tracked U.S. Retail OTC Anti-Infective CategoryShares 2000-2005 (E)
Table 2-4: IRI-Tracked U.S. Retail Sales of OTC Antifungals by Infection Type (Athlete’s Foot, Jock Itch, Vaginal Yeast Infection) 2000-2005 (E)
Figure 2-4: IRI-tracked U.S. Jock Itch and Athlete’s Foot QuarterlySales, 2004-2005
Table 2-5: U.S. Top 10 Cities Estimated to Experience Itch-RelatedInfections, 2005
Figure 2-5: U.S. FDA Drug Approvals, 1991-2004
Figure 2-6: National Health Expenditure, 1993-2003
Table 2-6: Projected U.S. Health Expenditures and Per CapitaIncome 2005-2010
Table 2-7: Younger U.S. Population (Under 15 Years) Projections 2000-2030
Table 2-8: Birth Rate and Women Age Group, 2002-2003
Figure 2-7: Spending for Prescription Drugs by Source of Funds (%)
Table 2-9: Uninsured Population by Age Group, 2003
Table 2-10: U.S. Generic Drug vs. Branded Drug Performance
Table 2-11: U.S. Top Five Generic Drug Marketers 2004 (Sales,Market Share, Growth from 2003)
Figure 2-8: U.S. Retail Anti-Infective Sales Projections, 2005-2010 (E)
Table 2-12: U.S. Retail Anti-Infective Sales Projections byCategory 2005-2010 (E)

Chapter Three: The Marketers

Table 3-1: IRI-Tracked Sales of Top 10 U.S. OTC Anti-InfectiveMarketers 2000-2005 (E)
Figure 3-1: U.S. Top 10 OTC Anti-Infective Marketers by MarketShare 2005 (E)
Table 3-2: IRI-Tracked Sales of Top 10 U.S. OTC Anti-InfectiveBrands 2000-2005 (E)
Table 3-3: IRI-Tracked Sales of Top 10 U.S. OTC AntifungalMarketers 2000-2005 (E)
Table 3-4: U.S. Top 10 Antifungal Marketers by Market Share 2000-2005 (E)
Table 3-5: IRI-Tracked Sales of Top 10 U.S. OTC AntifungalBrands 2000-2005 (E)
Table 3-6: IRI-Tracked Sales of Top 10 U.S. OTC Jock Itch TreatmentMarketers, 2000-2005 (E)
Table 3-7: U.S. Top 10 OTC Jock Itch Treatment Marketers by MarketShare, 2000-2005 (E)
Table 3-8: IRI-Tracked Sales of Top 10 U.S. OTC Jock Itch TreatmentBrands 2000-2005 (E)
Table 3-9: Top 10 Recognized Dermatology Brands in North America, 2005
Table 3-10: IRI-Tracked Sales of Top 10 U.S.OTC Vaginal Yeast InfectionTreatment Marketers 2000-2005 (E)
Table 3-11: U.S. Top 10 Vaginal Yeast Infection Treatment Marketers byMarket Share, 2000-2005 (E)
Table 3-12: IRI-Tracked Sales of Top 10 U.S. OTC Vaginal Yeast InfectionTreatment Brands, 2000-2005 (E)
Table 3-13: IRI-Tracked Sales of Top 10 U.S. OTC Athlete’s Foot TreatmentMarketers, 2000-2005 (E)
Table 3-14: U.S. Top 10 Athlete’s Foot Treatment Marketers by MarketShare, 2000-2005 (E)
Table 3-15: IRI-Tracked Sales of Top 10 U.S. OTC Athlete’s FootTreatment Brands, 2000-2005 (E)
Table 3-16: IRI-Tracked Sales of Top 10 U.S. OTC Antiseptic/AntibioticMarketers, 2000-2005 (E)
Table 3-17: U.S. Top 10 Antiseptic/Antibiotic Marketers by MarketShare, 2000-2005 (E)
Table 3-18: IRI-Tracked Sales of Top 10 U.S. OTC Antiseptic/AntibioticBrands, 2000-2005 (E)
Table 3-19: IRI-Tracked Sales of Top 10 U.S. OTC Anti-ParasiticTreatment Marketers, 2000-2005 (E)
Table 3-20: U.S. Top 10 Anti-Parasitic Treatment Marketers byMarket Share 2000-2005 (E)
Table 3-21: IRI-Tracked Sales of Top 10 U.S. OTC Anti-ParasiticTreatment Brands, 2000-2005 (E)
Figure 3-2: U.S. Private Label OTC Anti-Infective Sales, 2000-2005 (E)
Table 3-22: IRI-Tracked Sales of U.S. Private Label OTC Anti-Infectives byCategory (Antiseptics/Antibiotics, Anti-fungal Treatments,Antiparasitic Treatments) 2000-2005 (E)
Table 3-23: U.S. Private Label OTC Anti-Infective Market Share byCategory (Antiseptics/Antibiotics, Anti-fungal Treatments,Antiparasitic Treatments) 2000-2005 (E)

Chapter Four: The Consumer

Figure 4-1: U.S. Usage of First Aid Products, 2004 (%)
Figure 4-2: U.S. Usage of First Aid Products by Gender, 2005 (%)
Table 4-1: U.S. Usage of First Aid Bandages by Age, 2005
Table 4-2: U.S. Usage of First Aid Bandages, by Ethnicity, 2005
Figure 4-3: U.S. Usage of First Aid Products by Type, 2005
Table 4-3: U.S. Usage of First Aid Sprays, Gels and Wipes byHousehold Size, 2005
Table 4-4: U.S. Usage of First Aid Sprays, Gels and Wipes by Age ofChildren, 2005
Figure 4-4: U.S. First Aid Brands Used, 2005
Table 4-5: Demographic Profile of U.S. First Aid Product Users, 2005
Table 4-6: Demographic Profile of U.S. First Aid Cream, Gel andLiquid Users, 2005
Table 4-7: Demographic Profile of U.S. First Aid Ointment, Spray, Stick andWipe Users, 2005
Table 4-8: Demographic Profile of U.S. First Aid Users by Brand, 2005
Table 4-9: Demographic Profile of U.S. Store Brand First AidProduct Users, 2005
Table 4-10: U.S. Prevalence of Athlete’s Foot by Age, 2005
Figure 4-5: U.S. Prevalence of Athlete’s Foot by Gender, 2005
Figure 4-6: U.S. Prevalence of Nail Fungus by Gender, 2005
Table 4-11: U.S. Prevalence of Athlete’s Foot and Nail Fungus byEthnicity, 2005
Table 4-12: U.S. Prevalence of Athlete’s Foot and Nail Fungus byRegion, 2005
Table 4-13: U.S. Prevalence of Athlete’s Foot and Nail Fungus byEducation, 2005
Table 4-14: U.S. Foot Problem Prevalence, 2004
Table 4-15: Demographic Profile of U.S. Athlete's Foot Treatment User, 2005
Table 4-16: Demographic Profile of U.S. Nail Fungus Treatment User, 2005
Table 4-17: Demographic Profile of U.S. Athlete’s Foot-InfectedConsumer, 2005
Table 4-18: Demographic Profile of U.S. Nail Fungus-InfectedConsumer, 2005
Table 4-19: Demographic Profile of U.S. Women Using Yeast InfectionProducts, 2005
Table 4-20: Yeast Infection Treatment by Type Preferred(1, 3, and 7-Day) 2005
Table 4-21: Yeast Infection Treatment Usage by Ethnicity, 2005
Figure 4-7: U.S. Yeast Infection Brands Used, 2005
Table 4-22: Demographic Profile of U.S. Yeast Infection Treatment User byTreatment Type, 2005
Table 4-23: Demographic Profile of U.S. Yeast Infection TreatmentUser by Brand, 2005
Table 4-24: U.S. Consumer Attitudes w.r.t. Healthcare and Drugs, 2005
Table 4-25: Demographic Profile of U.S. Consumers Based on AttitudeTowards Store Brands, 2004

Chapter Five: Marketing Dynamics

Table 5-1: Ad Spend of Top 10 U.S. OTC Anti-Infective Marketers 2004
Table 5-2: Ad Spend and Media Channel of Top 10 U.S. OTC Anti-InfectiveBrands 2004
Table 5-3: U.S. Sales of Select OTC Anti-Infective Categories ThroughDrug Stores 2004
Table 5-4: Top Pharmacist Recommended Adhesive Bandages, 2005
Table 5-5: Top Pharmacist Recommended Athlete’s Foot Treatments, 2005
Table 5-6: Top Pharmacist Recommended Jock Itch Treatments, 2005
Table 5-7: Top Pharmacist Recommended Lice Treatments, 2005
Table 5-8: Top Pharmacist Recommended Nail Fungus Treatments, 2005
Table 5-9: Top Pharmacist Recommended Scar Treatments, 2005
Table 5-10: Top Pharmacist Recommended Vaginal Antifungals, 2005
Table 5-11: Top Pharmacist Recommended Wound Treatments, 2005
Table 5-12: Top 10 Marketers by Total SKUs Launched, 2005
Table 5-13: Top 10 Brands by Total SKUs Launched, 2005
Table 5-14: Top 10 Package Tags by Number of Brands, 2005
Table 5-15: U.S. Anti-Infective Product Introductions Tagged‘Instant/Quick’, 2005
Table 5-16: U.S. Anti-Infective Product Introductions Tagged‘Natural/Pure/Organic*’, 2005
Table 5-17: U.S. Anti-Infective Product Introductions for Teens/Kids, 2005
Table 5-18: U.S. Anti-Infective Product Introductions Tagged ‘Upscale’, 2005
Table 5-19: U.S. Anti-Infective Product Introductions for Women, 2005
Table 5-20: U.S. Anti-Infective Product Introductions Tagged‘No Allergy’, 2005
Table 5-21: U.S. Anti-Infective Product Introductions Tagged‘High Vitamins’, 2005
Table 5-22: Top 10 OTC Anti-Infective Flavors/Fragrances, 2005
Table 5-23: U.S. Anti-Infective Product Introductions Flavored/Scented‘Blend’, 2005
Table 5-24: U.S. Anti-Infective Product Introductions Flavored/Scented‘Lavender’, 2005
Table 5-25: U.S. Anti-Infective Product Introductions by Innovation, 2005

Chapter Six: Company Profiles

Table 6-1: Johnson & Johnson OTC Anti-Infective Brand Portfolio
Figure 6-1: IRI-Tracked U.S. Anti-infective Sales of Johnson & Johnson 2000-2005 (E)
Table 6-2: Pfizer Inc. OTC Anti-infective Brand Portfolio
Figure 6-2: Pfizer OTC Anti-infective Category Shares, 2005 (E)
Figure 6-3: IRI-Tracked U.S. Anti-infective Sales of Pfizer Inc., 2000-2005 (E)
Table 6-3: Bayer OTC Anti-infective Brand Portfolio
Figure 6-4: Bayer OTC Anti-infective Category Shares, 2005 (E)
Figure 6-5: IRI-Tracked U.S. Anti-infective Sales of Bayer, 2000-2005 (E)
Figure 6-6: IRI-Tracked U.S. Anti-infective Sales ofBristol-Myers Squibb, 2000-2005 (E)
Table 6-4: Novartis AG OTC Anti-infective Brand Portfolio
Figure 6-7: IRI-Tracked U.S. Anti-infective Sales ofNovartis AG, 2000-2005 (E) 198
Table 6-5: Bayer Anti-infective Brand Portfolio
Figure 6-8: Schering-Plough Corporation OTC Anti-infective CategoryShares, 2005 (E)
Figure 6-9: IRI-Tracked U.S. Anti-infective Sales of Schering Plough, 2000-2005 (E)
Table 6-6: Combe Inc. OTC Anti-infective Brand Portfolio
Figure 6-10: Combe Inc. OTC Anti-infective Category Shares, 2005 (E)
Figure 6-11: IRI-Tracked U.S. Anti-infective Sales of Combe Inc., 2000-2005 (E)
Figure 6-12: Chattem Inc. Business Segments as Percentage ofWorldwide Sales, 2004
Figure 6-13: Chattem Inc. OTC Anti-infective Category Shares, 2005 (E)
Figure 6-14: IRI-Tracked U.S. Anti-infective Sales ofChattem Inc., 2000-2005 (E)
Figure 6-15: IRI-Tracked U.S. Anti-infective Sales ofMerz Pharmaceuticals, 2000-2005 (E)
Table 6-7: Beiersdorf Inc. OTC Anti-infective Brand Portfolio
Figure 6-16: Beiersdorf Inc. OTC Anti-infective Category Shares, 2005 (E)
Figure 6-17: IRI-Tracked U.S. Anti-infective Sales ofBeiersdorf Inc., 2000-2005 (E)
Figure 6-18: IRI-Tracked U.S. Anti-infective Sales of TaroPharmaceuticals, 2000-2005 (E)
Figure 6-19: IRI-Tracked U.S. Anti-infective Sales of StiefelLaboratories, 2000-2005 (E)
Figure 6-20: IRI-Tracked U.S. Anti-infective Sales of Alva-AmcoPharmacal, 2000-2005 (E)
Table 6-8: Becton Dickinson Company Sales, by Region, 2004
Table 6-9: Becton Dickinson Company Sales, by Division, 2004Figure 6-21: IRI-Tracked U.S. Anti-infective Sales of BectonDickinson, 2000-2005 (E)
Table 6-10: Playtex Products Inc. Sales, by Division, 2004
Figure 6-22: IRI-Tracked U.S. Anti-infective Sales of PlaytexProducts, 2000-2005 (E)

Other users found this report page using the following search terms: over the counter otc Antifungals Antiseptic Antibiotics Antiparasitics otc market over counter anti us antiseptic infection treatment drugs

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

The U.S. Market for Over-the-Counter Anti-Infectives

Credit Card Details

Invoice Details

Table of Contents